| 000 | 02700 a2200769 4500 | ||
|---|---|---|---|
| 005 | 20250516053957.0 | ||
| 264 | 0 | _c20120320 | |
| 008 | 201203s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-011-1730-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSkarlos, P | |
| 245 | 0 | 0 |
_aTriple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cFeb 2012 |
||
| 300 |
_a533-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aCluster Analysis |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEstrogen Receptor alpha _xgenetics |
| 650 | 0 | 4 |
_aEstrogen Receptor beta _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOutcome Assessment, Health Care _xmethods |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xgenetics |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xgenetics |
| 650 | 0 | 4 |
_aReceptors, Progesterone _xgenetics |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 |
_aTranslational Research, Biomedical _xmethods |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aChristodoulou, C | |
| 700 | 1 | _aKalogeras, K T | |
| 700 | 1 | _aEleftheraki, A G | |
| 700 | 1 | _aBobos, M | |
| 700 | 1 | _aBatistatou, A | |
| 700 | 1 | _aValavanis, C | |
| 700 | 1 | _aTzaida, O | |
| 700 | 1 | _aTimotheadou, E | |
| 700 | 1 | _aKronenwett, R | |
| 700 | 1 | _aWirtz, R M | |
| 700 | 1 | _aKostopoulos, I | |
| 700 | 1 | _aTelevantou, D | |
| 700 | 1 | _aKoutselini, E | |
| 700 | 1 | _aPapaspirou, I | |
| 700 | 1 | _aPapadimitriou, C A | |
| 700 | 1 | _aPectasides, D | |
| 700 | 1 | _aGogas, H | |
| 700 | 1 | _aAravantinos, G | |
| 700 | 1 | _aPavlidis, N | |
| 700 | 1 | _aArapantoni, P | |
| 700 | 1 | _aSkarlos, D V | |
| 700 | 1 | _aFountzilas, G | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 69 _gno. 2 _gp. 533-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-011-1730-9 _zAvailable from publisher's website |
| 999 |
_c21141672 _d21141672 |
||